Beam Therapeutics Inc.(BEAM)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Beam Therapeutics Inc. (BEAM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BEAM at 34.2/100 on a 32-signal composite quality model, placing it at rank #2,357 of 2,962 stocks — the bottom half of the AI-ranked universe. BEAM scores in the top quartile across revenue growth (95.3). Areas of concern include earnings quality (1.3) and free cash flow (4.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Beam Therapeutics Inc. reports quarterly revenue of $490.0K, net income of $-122.7M, free cash flow of $-68.5M. Top institutional holders of BEAM by reported 13-F value include FMR, FARALLON CAPITAL MANAGEMENT, ARK Investment Management, based on the most recent SEC filings. BEAM trades on the Nasdaq exchange and files with the SEC under CIK 1745999. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BEAM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Beam Therapeutics Inc. directly from SEC EDGAR.